Speciality: Cardiology
Description:
A warm welcome to all the medical professionals in this interesting session on understanding the management of ATTRCM with the use of Vyndamax.
ATTR-CM is a protein deposition disorder that affects the heart, leading to structural damage and heart failure. It can be classified as wild type ATTR-CM or hereditary ATTR-CM.
Diagnostic tools like scintigraphy and hematologic tests are essential for confirming the diagnosis of ATTR-CM. Scintigraphy helps visualize the extent of amyloid deposition, while hematologic tests detect monoclonal proteins.
Vyndamax, a drug by Pfizer, has shown promising results in the treatment of ATTR-CM. It stabilizes the protein and prevents further amyloid deposition, improving patient outcomes and reducing mortality.
Therefore, get an overall knowledge regarding understanding the importance of Tafamidis drug in controlling ATTRCM. Listen to the webinar, grab the knowledge that is shared, and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.
2.
More Data from Population-Based Studies Show CRC Screening Lowers Cancer Death Risk.
3.
What Role Should Genomic Classifier Testing Play in Prostate Cancer?
4.
A new mechanism of radioresistance formation demonstrated in lung adenocarcinoma
5.
Squeezing through tiny blood vessels may trigger melanoma cells to spread
1.
The Future of Cancer Care: Genetics, Support Systems, and Emerging Therapies
2.
Everything You Need to Know About Leiomyomas: A Comprehensive Guide
3.
The Importance of Corrected Calcium Levels in Managing Health Conditions
4.
How Parvovirus B19 Affects Pregnant Women and Their Unborn Babies
5.
Cowden Syndrome and Cancer: Understanding the Risk Factors
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Dissecting Molecular differences between EGFR Exon 19 deletion and Exon 21 L858R Mutations
2.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part II
3.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part V
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VIII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation